Table 2.
(A) The predictive factors of HBsAg clearance at week 48 in all Peg-IFN-treated patients and (B) prediction of HBsAg loss at week 48 in patients who received Peg-IFN treatment.
| (A) Predictors | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| OR | 95%CI | p | OR | 95%CI | p | ||
| Age, years | 0.984 | 0.950–1.019 | 0.369 | ||||
| Gender (male) | 2.253 | 0.999–5.082 | 0.005 | 1.214 | 0.350–4.211 | 0.760 | |
| Treatment (NA add-on Peg-IFN) | 1.634 | 0.784–3.406 | 0.190 | 0.382 | 0.108–1.355 | 0.136 | |
| Baseline HBsAg level IU/mL | 0.998 | 0.991–0.997 | 0.000 | 0.993 | 0.989–0.997 | 0.001 | |
| HBsAg level at 12 weeks, IU/mL | 0.985 | 0.978–0.992 | 0.000 | 1.002 | 0.992–1.011 | 0.722 | |
| HBsAg level at 24 weeks, IU/mL | 0.965 | 0.947–0.984 | 0.000 | 1.006 | 0.987–1.026 | 0.527 | |
| Baseline HBV DNA<100 IU/mL | 1.355 | 0.504–3.640 | 0.547 | ||||
| HBV DNA<100 IU/mL at week 12 | 0.313 | 0.280–3.552 | 0.349 | ||||
| HBsAg decline from baseline to week 12, % | 17.192 | 5.945–49.717 | 0.000 | 4.221 | 1.156–15.409 | 0.029 | |
| HBsAg decline from baseline to week 24, % | 131.816 | 48.054–361.586 | 0.000 | 50.815 | 6.154–419.603 | 0.006 | |
| Baseline ALT, *ULN | 1.013 | 0.988–1.040 | 0.314 | ||||
| ALT elevation at week 12, *ULN | 1.076 | 0.917–1.263 | 0.371 | ||||
| ALT elevation at week 12, *ULN | 1.165 | 0.868–1.563 | 0.310 | ||||
| (B) Prediction model | Area | Cut-off point | Sensitivity | Specificity | p | ||
| Baseline HBsAg level IU/mL | 0.770 | 72 | 77.5% | 69.7% | <0.001 | ||
| HBsAg decline from baseline to week 12, % | 0.877 | 80 | 80.3% | 83.7% | <0.001 | ||
| HBsAg decline from baseline to week 24, % | 0.915 | 98 | 90.8% | 95.9% | <0.001 | ||
OR, odds ratios; CI, confidence interval; HBsAg, hepatitis B surface antigen; HBV DNA, hepatitis B virus-deoxyribonucleic acid; ALT, alanine aminotransferase; ULN, upper limit of normal value; Peg-IFN, pegylated interferon; NA, nucleoside analog.